OrganaBio, the Contract Technology Development and Manufacturing Organization (CTDMO) specializing in solutions for cell and immunotherapy development, today announces the official launch of Cell Processing and Cryopreservation (CPC) Services, a new division of OrganaBio.
FDA grants priority review for Zealand Pharma’s dasiglucagon
Dasiglucagon is intended for usage in infants aged seven days and above with congenital hyperinsulinism. Credit: Liudmila Fadzeyeva / Shutterstock.com. The US Food and Drug